Literature DB >> 29272375

De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series.

Manuel B Braga Neto1, Martin Gregory2, Guilherme P Ramos1, Edward V Loftus1, Matthew A Ciorba2, David H Bruining1, Fateh Bazerbachi1, Barham K Abu Dayyeh1, Vladimir M Kushnir2, Meera Shah3, Maria L Collazo-Clavell3, Laura E Raffals1, Parakkal Deepak1,2.   

Abstract

BACKGROUND: Case reports of inflammatory bowel diseases [IBD] have been reported in patients with a history of bariatric surgery. Our aim was to characterize patients who were diagnosed with IBD after having undergone bariatric surgery.
METHODS: Electronic medical records were reviewed at two institutions to identify patients who developed de-novo Crohn's disease or ulcerative colitis [UC] after bariatric surgery. Data on demographics, type of bariatric surgical procedure, IBD subtype, phenotype and medication usage were obtained. The incidence rate of de-novo IBD after bariatric surgery [per 100000 person-years] and standardized incidence ratio [SIR] were estimated from a prospective bariatric surgery database.
RESULTS: A total of 44 patients with de-novo IBD after bariatric surgery were identified [31 Crohn's disease, 12 UC, one IBD unclassified]. Most patients were female [88.6%], with median age at IBD onset of 44 years [IQR, 37-52] and median time to IBD diagnosis after bariatric surgery of 7 years [IQR, 3-10]. Sixty-eight per cent underwent Roux-en-Y gastric bypass. In the prospective database, the incidence of IBD in patients who underwent bariatric surgery was 26.7 per 100000 person-years [4.5 for UC and 22.3 for Crohn's disease]. The age-adjusted SIR ranged from 3.56 in the 40-49 year age group to 4.73 in the 30-39 year age group.
CONCLUSION: We described a case series of patients developing de-novo IBD after bariatric surgery. There appears to be a numerically higher incidence of Crohn's disease in this population. Confirmation of causality is required in larger patient cohorts.

Entities:  

Mesh:

Year:  2018        PMID: 29272375     DOI: 10.1093/ecco-jcc/jjx177

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

1.  Impact of Obesity on the Management of Inflammatory Bowel Disease.

Authors:  Amanda M Johnson; Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-07

2.  TGR5 Protects Against Colitis in Mice, but Vertical Sleeve Gastrectomy Increases Colitis Severity.

Authors:  Darline Garibay; Karolina E Zaborska; Michael Shanahan; Qiaonan Zheng; Katie M Kelly; David C Montrose; Andrew J Dannenberg; Andrew D Miller; Praveen Sethupathy; Bethany P Cummings
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

3.  Obesity and Weight Gain Since Early Adulthood Are Associated With a Lower Risk of Microscopic Colitis.

Authors:  Po-Hong Liu; Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Ola Olen; Jonas F Ludvigsson; James M Richter; Andrew T Chan; Hamed Khalili
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12-06       Impact factor: 11.382

4.  Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.

Authors:  Thomas Greuter; Frédéric Porchet; Manuel B Braga-Neto; Jean-Benoit Rossel; Luc Biedermann; Philipp Schreiner; Michael Scharl; Alain M Schoepfer; Ekaterina Safroneeva; Alex Straumann; Gerhard Rogler; Stephan R Vavricka
Journal:  United European Gastroenterol J       Date:  2020-12       Impact factor: 4.623

5.  Bariatric Surgery and Risk of New-onset Inflammatory Bowel Disease: A Nationwide Cohort Study.

Authors:  Kristine H Allin; Rikke K Jacobsen; Ryan C Ungaro; Jean-Frederic Colombel; Alexander Egeberg; Marie Villumsen; Tine Jess
Journal:  J Crohns Colitis       Date:  2021-09-25       Impact factor: 9.071

Review 6.  Secondary causes of inflammatory bowel diseases.

Authors:  Yezaz A Ghouri; Veysel Tahan; Bo Shen
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.